We recently compiled a list of the 10 Best Low Volatility Stocks to Invest in Now. In this article, we are going to take a ...

That is, the point at which a drug loses patent protection and will have to compete with biosimilar competition. For Merck, ...

Merck's consistent dividend payments over 34 years, healthy balance sheet, and attractive valuation highlight its investment ...

The company also has a solid dividend record. Its payouts have increased by 71% in the past decade, and it currently offers a ...

Its top-selling treatment, Keytruda, will lose patent protection in a few years. Then Merck will face biosimilar competition ...

The drugmaker emphasized plans to move further away from singular reliance on Keytruda while reporting solid sales growth in ...

Shares in Merck & Co were more than 2% lower as New York trading entered its latter half on Thursday. The US pharma giant ...

The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health ...

Merck reported a mixed third quarter update on Thursday, cutting guidance even as earnings topped market expectations. The readout didn’t seem to be enough to change the narrative around the stock, ...

Teena Thacker - Read the latest articles by Teena Thacker on the trending topics, exclusive information, Analysis and top headlines at Times of India.

Cabozantinib is the active ingredient in two of Exelixis' three approved drugs (Cabometyx and Cometriq) and its strongest US patent covering cabozantinib’s composition of matter expires in 2030.

Cash receipts from customers in Q1 FY25 were $20k. During the quarter, Immutep received a €2,194,918 (~A$3,602,362) research ...